Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone vs placebo in idiopathic pulmonary fibrosis
CTR20140067Phase 2Completed
- Sponsor
- Nanjing Huawei Pharmaceutical Technology Development
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Nanjing Huawei Pharmaceutical Technology Development. Started Apr 2016; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20140067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140067.